Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, as you might guess, is rather limited. We plan to stay home and catch up on our reading, indulge in a little binge-watching on the telly, and otherwise take stock of  the world. And what about you? This is a good time to review your plans for remaining healthy. Perhaps you can reach out to those who may be most vulnerable, such as the elderly, to see how they are doing. Or simply take stock. Well, whatever you do, have a grand time. But try not to panic. Enjoy, and see you soon.

Dozens of drug makers are scrambling to develop vaccines that could prevent people from contracting the new coronavirus, or therapies to treat people infected with the respiratory disease it causes, The Wall Street Journal tells us. Testing of several potential drugs and vaccines has already started, and more trials are in the works. Additional studies could follow if researchers find that products approved for other uses, or even ones they discarded, show promise in their labs tackling the virus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.